Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Nat Rev Drug Discov. 2022 May 30;21(12):899–914. doi: 10.1038/s41573-022-00472-w

Figure 4.

Figure 4.

Utility of active / inactive compound pairs to address safety questions for compound series with unknown target(s) or MoA(s). A) Profiles in the BioPrint pharmacology panel148 of PCSK9 secretion inhibitor (R)-IMPP and its inactive analogue (S)-IMPP. Figure adapted with permission from ref 49 B) In vivo toxicology results following multi day dosing of of cystic fibrosis lead Compound 1 (+) and its inactive analogue Compound 2 (−). Blue coloring indicates the compound was tolerated while red lettering indicates it was not. Cave: average in vivo concentration, Ceff: predicted in vivo effective concentration for Compound 1.